Gy were delivered at point A by brachytherapy to all patients.
INTRODUCTION
Standard treatment for cervical cancer is a combination of external beam radiation therapy (EBRT), chemotherapy, and intracavitary brachytherapy. [1] Intracavitary radiation, which is especially important for locally advanced cancer, has been done since the 1900s and it has been shown to contribute to the improvement of local control, survival rate, and disease-free period more in combination with EBRT than when using EBRT alone. [2] [3] [4] The Manchester system was deloped in 1930s, which was based on prescription to point A; 2 cm lateral to the central canal of the uterus and 2 cm up from the mucous membrane of the lateral fornix, in the axis of the uterus. [5] It has yielded comparatively good treatment results.
However, this prescribed dose point was based on 2D X-ray films and it could not visualize the cervical tumor. Furthermore, the dose coverage was insufficient in cases with a large tumor, a narrow vagina, a cervical canal impermissible to insertion, parametrial invasion, pelvic wall invasion, or infiltration of the vagina. [6] In 1980s, radiotherapy techniques advanced and it became possible to make plan based on 3D images, such as computed tomography (CT) and magnetic resonance imaging(MRI). International Commission on Radiation Units and Measurements (ICRU) Report 38 was issued in 1985, indicating irradiation target volume rather than point A and specifying reference points for the rectum and bladder. [10] HR-CTV is defined as CTV includes the residual tumor at the time of brachytherapy, whole cervix, adjacent residual pathologic tissue if present. It is the volume bearing the high risk of recurrence. 7 The evaluation of organs at risk (OAR) has shifted away from ICRU Report 38 reference points to using a dose-volume histogram (DVH) approach. [8 → 9] D2cm ³ for the bladder and rectum, which are defined as the minimum doses delivered to 2cm³ of the organ volume, are used for indicators of toxicity.
[10] Furthermore, many studies reported that IGBT combined with radio-chemotherapy leads to better local control, overall survival, and cancer-specific survival.
However, Point A represents the most used parameter in gyneocologic brachytherapy worldwide including Japan and it is now transition period to IGBT. Our hospital is also considering the switch to IGBT. In were analyzed in order to evaluate dose distribution.
TREATMENT
All patients had an MRI of the pelvis taken before treatment. EBRT prescription dose was 50-60 Gy delivered to the whole pelvis and pelvic para-aortic region in 25-30 fractions using 10 MV X-rays. A midline block was inserted after delivering 30-40 Gy. HDR-BT was performed using the 192Ir remote-controlled afterloading system (RALS). A CT scanner was installed in the brachytherapy treatment room, and after each brachytherapy application, a pelvic CT was performed. The images were imported to a 3D brachytherapy treatment planning system and a plan was made.
All patients had 6Gy per fraction delivered to point A by brachytherapy, with a total dose of 12-24 Gy. The iridium source strength was 370 GBq. HDR-BT was done once a week with concurrent central shielding EBRT. Vaginal packing was used to 9 reduce rectum irradiation.
DOSE EVALUATION
After the first HDR-BT fraction, HR-CTV, bladder, and rectum contours were re-delineated according to ICRU Report 89 by two radiation oncologists using the MR images available at the time of diagnosis. HR-CTV was presumed to be palpable and visible by clinical examination and detectable using MRI (high intensity in
T2-weighted images). A dose volume histogram(DVH) planning,
which is a histogram relating radiation dose to tissue volume, was generated for each structure. From the DVH analysis, HR-CTV D90, and D2cm ³ of the rectum and bladder were obtained. These parameters were analyzed in each T subgroup. Correlations between HR-CTV D90 or OAR D2cm³ and HR-CTV volume were performed using Spearman's rank correlation coefficient.
RESULTS
PATIENT CHARACTERISTICS (Table 1) .
Sixty-eight patients with cervical cancer were eligible for this analysis. Table   2 ). Except in the T4 case, the HR-CTV D90 value seems to decrease as T stage progresses (Table 2, Figure 1 ). Especially in T3b cases, it was difficult to cover the HR-CTV with sufficient dose. The mean OAR D2cm³ was 667.8 cGy for the bladder (range: 316.2-1272.5 cGy) and 508.1 cGy for the rectum (202.8-852.7 cGy) (Table2). There were no significant differences between HR-CTV volume and OAR dose.
There was a correlation between HR-CTV D90 and HR-CTV volume (Figure 2 ). HR-CTV D90 value decreased when HR-CTV was large (p<0.001, r=-0.5836, Spearman's correlation). The value of HR-CTV D90 was often less than 600cGy when HR-CTV exceeded 40cm³. [15] The guideline would help us for better coverage of CTV.
In terms of external irradiation, some institutions use a central shielding technique, which is commonly used in Japan or Southeast Asia, in order to deliver high doses to pelvic nodes and lower the irradiation doses to the bladder and rectum while permitting an HR-CTV D90(cGY) Figure 2 . Correlation between the dose to 90% of the high-risk clinical target volume (HR-CTV D90) and HR-CTV （p＜0.001, Spearman rank correlation test） There was a correlation between HR-CTV D90 and HR-CTV volume. HR-CTV D90 value decreased when HR-CTV was large. The value of HR-CTV D90 is often less than 600cGy when HR-CTV is over 40cm³. 
